Two treatments, two different problems

Patients researching ChondroFiller and Arthrosamid are often asking the wrong question. The choice between them is not a matter of which works better — it is a matter of which problem is actually present in the knee.

ChondroFiller is a collagen scaffold placed into a discrete, focal cartilage defect. It works by recruiting the body's own progenitor cells to support endogenous cartilage repair — a regenerative mechanism aimed at restoring structure. Arthrosamid, by contrast, targets a different anatomy entirely: it cushions the synovial lining rather than filling a cartilage lesion, providing durable mechanical relief in diffuse osteoarthritic joints where no single repairable defect exists.

The selection is driven by what the MRI shows, not by patient preference between two otherwise equivalent options. Both are delivered as ultrasound-guided outpatient injections — neither requires surgery or theatre admission.

For some patients, MRI reveals both a focal defect and widespread OA-pattern disease. That scenario, and how the two treatments can work together, is covered later in the article.

ChondroFiller: a scaffold for focal cartilage defects

Manufactured in Germany by meidrix biomedicals GmbH, ChondroFiller is a CE-marked Class III medical device: a sterile, cell-free Type I collagen scaffold supplied in a two-chamber syringe. At MSK Doctors it is delivered as an ultrasound-guided outpatient injection — the matrix is placed directly into the cartilage defect, where it polymerises in approximately 3–5 minutes into a dimensionally stable hydrogel that conforms to the lesion geometry, without bone drilling or fibrin glue.

The mechanism is acellular matrix-induced chondrogenesis. In plain terms: the scaffold contains no donor cells — it creates a physical environment that draws in the patient's own mesenchymal progenitor cells from the surrounding tissue. Those cells migrate in, differentiate towards chondrocytes, and progressively deposit new cartilage matrix. This is endogenous repair guided by the scaffold, not an injection that directly replaces missing tissue. Functional improvement is typically noticed within three months; full structural maturation of the new tissue takes 9–12 months.

ChondroFiller is indicated for focal Grade III and IV cartilage defects. It works best in younger or active individuals with a contained, identifiable lesion and sufficient residual regenerative capacity — patients with end-stage bone-on-bone osteoarthritis are not suitable candidates, as the cellular environment required is no longer present. Across published European cohorts spanning close to two decades, 70–85% of treated patients achieve meaningful pain reduction and measurable improvement in joint function.

The quantity of product needed — and therefore the guide cost — is determined by defect size and location, established from imaging review before any treatment plan is finalised.

Arthrosamid: mechanical cushioning for OA-pattern knees

Unlike ChondroFiller, Arthrosamid does not target the articular cartilage surface at all. It is a single-dose injectable hydrogel — 97.5% water and 2.5% cross-linked polyacrylamide (iPAAG) — delivered in a single outpatient appointment under local anaesthesia. Once injected, it integrates permanently into the synovial membrane, forming a sub-synovial cushioning layer that reduces intra-articular friction and mechanical load across the joint.

That permanence is worth understanding clearly: the hydrogel remains in the joint indefinitely, which is part of what gives it durability. It does not break down or require top-up injections. It is not, however, a structural repair — it does not fill a cartilage defect, stimulate cell recruitment, or rebuild articular tissue. Its role is mechanical and symptomatic.

Arthrosamid is indicated for mild-to-moderate knee osteoarthritis. It is explicitly less suitable for severe OA, where arthroplasty typically provides more reliable outcomes, and it is not appropriate for inflammatory (rheumatoid) arthritis. For patients in its indicated range, clinical cohort data support sustained pain reduction for two to five years from a single injection — a meaningfully longer duration than hyaluronic acid viscosupplementation, which works through a different and non-permanent mechanism. Symptom relief typically begins within four weeks of treatment.

For patients whose MRI shows diffuse OA-pattern disease without a discrete, repairable focal defect, Arthrosamid may be the more clinically appropriate option — though individual suitability should always be confirmed at consultant assessment.

What the evidence shows — and where the gaps are

Evidence for these two treatments does not sit on a common scale — and that is the point. The patients treated with ChondroFiller and those treated with Arthrosamid are, by clinical design, different populations: focal contained defects in one group, diffuse OA-pattern disease in the other. Comparing their published outcome data as though the treatments were competing for the same indication misconstrues what each evidence base is trying to show.

ChondroFiller carries close to two decades of European cohort data across multiple joint types — knee, hip, and others — making it one of the longer-running published records for an injectable collagen scaffold. Arthrosamid's evidence base is newer but larger in scale for its specific indication: contemporary registry data in OA knee populations show sustained pain reduction across two to three years of follow-up, with consistency across cohorts that has helped establish it as a durable option in that patient group.

No head-to-head randomised controlled trial comparing the two treatments has been conducted — nor is one straightforward to design, precisely because the indications do not overlap. That absence does not weaken either treatment's position; it reflects the reality that they are not substitutes. The more useful question is not which treatment has a stronger evidence base in the abstract, but which treatment the evidence supports for what your MRI actually shows. That determination requires imaging review and consultant assessment, not a literature ranking.

When both treatments are used in the same appointment

Some patients present with a picture that spans both pathologies: a discrete focal cartilage lesion on one part of the articular surface alongside broader OA-driven synovial inflammation in the same joint. For those patients, a consultant may recommend both injections in a single outpatient appointment — not because the treatments overlap, but precisely because they do not. Each is addressing a different anatomical target, and delivering both at once avoids a second visit.

The clinical logic of pairing them rests on that anatomical separation. Because the two products work at different sites and through entirely different mechanisms, they do not compete or replicate each other's role. One is the regenerative scaffold component; the other is the mechanical cushioning component. Collapsing them into a generic 'double injection' misrepresents what is happening biologically.

Sequencing and recovery expectations for the combination pathway should be discussed in full with the treating consultant before proceeding. The timeline for structural benefit from the collagen scaffold — typically felt within three months, with maturation continuing over nine to twelve months — differs from the faster onset of the hydrogel's mechanical effect, usually within four weeks. Combined guide costs will also be higher than either treatment alone, and these should be confirmed at the imaging-review stage rather than assumed.

Combination use is a specialist clinical decision, not a default upgrade. It is appropriate only where the MRI and patient profile specifically support both components.

Getting the right match: the MSK Doctors pathway

The decision between ChondroFiller, Arthrosamid, or a combination cannot be made from symptom history alone — it turns on what the imaging shows. A focal contained defect with residual regenerative capacity points in a different direction from diffuse OA-pattern changes with no discrete repairable lesion, and a picture that includes both elements may genuinely warrant both injections. That determination requires an up-to-date MRI reviewed by a musculoskeletal consultant familiar with both pathways before any treatment is proposed.

For patients in Lincolnshire and the wider non-London catchment, MSK Doctors offers consultant-led assessment without a GP referral and without NHS waiting times. The Sleaford site — where an Open MRI scanner sits within the Regeneration Hub — supports the imaging review and treatment planning pathway in one location; the Grantham diagnostics and consultation centre provides an additional access point for the same pathway. Defect size, grade, and regenerative capacity are confirmed from imaging before any injection is considered, not after.

London-based patients are typically assessed through London Cartilage Clinic, the group's London arm.

Appointments can be booked without a referral at mskdoctors.com.